• Palbociclib plus endocrine therapy does not lower QOL in BIPOC

    3 monthes ago - By Healio

    Palbociclib plus endocrine therapy was not associated with lowered quality of life among Black, indigenous and people of color with HR-positive, HER2-negative advanced breast cancer, according to research presented at ASCO 2021.
    “The PALOMA study suggested that palbociclib was able to maintain quality of life using patient-reported outcomes,” Gabrielle Betty Rocque, MD, MSPH, FASCO, associate professor of medicine in the divisions of hematology & oncology and gerontology, geriatrics, & palliative care at the University of Alabama at Birmingham, said during the presentation.
    Read more ...